Biotech
-
Eli Lilly’s Obesity Pill Could Be a Game-Changer — But Here’s Why Zepbound Already Has a Giant Lead
Eli Lilly has taken a commanding position in the obesity drug market with its GLP-1 agonist Zepbound, and now the…
Read More » -
BioNTech’s High-Stakes Leap Into Cancer: Inside The $1.25 Billion CureVac Deal & Its Oncology Ambitions
BioNTech’s recent $1.25 billion all-stock acquisition of former rival CureVac marks a definitive shift in strategy—away from COVID-19 vaccine reliance…
Read More » -
Bristol Myers’ $11.1 Billion Bet on BioNTech: Is Oncology The New Growth Engine?
Bristol Myers has inked a transformative partnership for BNT327, a bispecific PD-L1/VEGF-A antibody developed by BioNTech, with a $1.5 billion…
Read More » -
Eli Lilly’s $1 Billion Bet On SiteOne: Can Non-Opioid Pain Drugs Reshape The Pharma Giant’s Future?
Eli Lilly has agreed to acquire SiteOne Therapeutics, a clinical-stage biotech specializing in small molecule inhibitors of sodium channels involved…
Read More » -
Aspire Biopharma CEO Interview: Disrupting Drug Delivery with Sublingual Tech
SmallCaps Daily sits down with ASBP’s CEO Kraig Higginson to discuss the company's disruptive technology and the expected clinical and…
Read More » -
Is Cytokinetics The Next Big Takeover Target? Here’s What You Need to Know!
Cytokinetics has recently surged amid renewed takeover speculation as reported on a Betaville "uncooked" alert, with multiple large pharmaceutical firms…
Read More » -
Arcutis Biotherapeutics Surges Amid Takeover Speculation: Why Large Pharma Should Pay Attention!
According to a Betaville "uncooked" alert, an unidentified European pharmaceutical company is reportedly exploring a bid for Arcutis Biotherapeutics.
Read More » -
Legend Biotech: Why The Recent Takeover Speculation Is Worth Your Attention!
Legend Biotech has drawn significant attention recently due to rumors of a potential takeover, with a 4% surge in its…
Read More » -
The Biotech Stock Soaring 63% on Unprecedented Cancer Trial Results – Meet Janux Therapeutics
On December 3, 2024, the company announced groundbreaking results for its lead drug candidate, JANX007, a tumor-activated T-cell engager targeting…
Read More » -
Why Maravai LifeSciences Could Be a Perfect Acquisition Target for Repligen
Maravai LifeSciences has recently caught the attention of Repligen as a potential acquisition target, marking it as a significant player…
Read More »
